Pharmacokinetics of doripenem in patients with renal dysfunction
|
Accession number;05A0663319
|
| Title;Pharmacokinetics of doripenem in patients with renal dysfunction |
| Author;
UEHARA SHIN'YA
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
MURAO WATARU
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
SENO YUKO
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
ANDO EIICHI
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
MONDEN KOICHI
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
KARIYAMA REIKO
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
TSUGAWA MASAYA
(Okayama Munic. Hosp.)
NAKASHIMA MITSUYOSHI
(Hamamatsushipitiken)
KUMON HIROMI
(Graduate School of Medicine and Dentistry, Okayama Univ., JPN)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.53;NO.Supplement 1;PAGE.130-135(2005)
|
| Figure&Table&Reference;FIG.3, TBL.4, REF.8 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We compared pharmacokinetic profiles of doripenem (DRPM) in patients with renal dysfunction to those in healthy volunteers in a Phase I study. Patients with renal dysfunction were divided into 3 groups based on creatinine clearance (Ccr): mild dysfunction with 50 .LEQ. Ccr < 70 mL/min (Group I, n=4), moderate dysfunction with 30 .LEQ. Ccr < 50 mL/min (Group II, n=6), and severe dysfunction with Ccr < 30 mL/min (Group III, n=2). Area under the blood concentration curve (AUC) in healthy volunteers after DRPM administration (250 mg) was 20.26 .MU.g h/mL, while AUCs in Groups I, II and III were 40.55 .MU.g h/mL, 48.21 .MU.g h/mL and 64.31 .MU.g h/mL. These results indicated that AUC increased with the severity of renal dysfunction. Half-lives were 0.90, 1.98, 2.16, and 3.56 h in healthy volunteers, Group I, Group II, and Group III, and prolonged based on renal dysfunction severity. Urinary excretion (0-24 h) was 74.5%, 63.9%, 67.3%, and 58.2% in healthy volunteers, Group I, Groroup II, and Group III, decreasing based on renal dysfunction severity. No adverse reactions were observed. Our results suggest that the DRPM dosage and dosing interval should be determined carefully when in administration to patients with renal dysfunction. (author abst.) |
|
|
|
Related Articles;
|
|
